Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
2006 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pancreatic Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively. Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 14 Pancreatic Cancer Overview 15 Therapeutics Development 16 Pancreatic Cancer - Therapeutics under Development by Companies 18 Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 45 Pancreatic Cancer - Pipeline Products Glance 49 Pancreatic Cancer - Products under Development by Companies 53 Pancreatic Cancer - Products under Investigation by Universities/Institutes 88 Pancreatic Cancer - Companies Involved in Therapeutics Development 93 Pancreatic Cancer - Therapeutics Assessment 397 Drug Profiles 478 Pancreatic Cancer - Dormant Projects 1889 Pancreatic Cancer - Discontinued Products 1922 Pancreatic Cancer - Product Development Milestones 1929 Appendix 1942
List of Tables
Number of Products under Development for Pancreatic Cancer, H2 2016 79 Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80 Number of Products under Development by Companies, H2 2016 82 Number of Products under Development by Companies, H2 2016 (Contd..1) 83 Number of Products under Development by Companies, H2 2016 (Contd..2) 84 Number of Products under Development by Companies, H2 2016 (Contd..3) 85 Number of Products under Development by Companies, H2 2016 (Contd..4) 86 Number of Products under Development by Companies, H2 2016 (Contd..5) 87 Number of Products under Development by Companies, H2 2016 (Contd..6) 88 Number of Products under Development by Companies, H2 2016 (Contd..7) 89 Number of Products under Development by Companies, H2 2016 (Contd..8) 90 Number of Products under Development by Companies, H2 2016 (Contd..9) 91 Number of Products under Development by Companies, H2 2016 (Contd..10) 92 Number of Products under Development by Companies, H2 2016 (Contd..11) 93 Number of Products under Development by Companies, H2 2016 (Contd..12) 94 Number of Products under Development by Companies, H2 2016 (Contd..13) 95 Number of Products under Development by Companies, H2 2016 (Contd..14) 96 Number of Products under Development by Companies, H2 2016 (Contd..15) 97 Number of Products under Development by Companies, H2 2016 (Contd..16) 98 Number of Products under Development by Companies, H2 2016 (Contd..17) 99 Number of Products under Development by Companies, H2 2016 (Contd..18) 100 Number of Products under Development by Companies, H2 2016 (Contd..19) 101 Number of Products under Development by Companies, H2 2016 (Contd..20) 102 Number of Products under Development by Companies, H2 2016 (Contd..21) 103 Number of Products under Development by Companies, H2 2016 (Contd..22) 104 Number of Products under Development by Companies, H2 2016 (Contd..23) 105 Number of Products under Development by Companies, H2 2016 (Contd..24) 106 Number of Products under Development by Companies, H2 2016 (Contd..25) 107 Number of Products under Investigation by Universities/Institutes, H2 2016 108 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 109 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 110 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 111 Comparative Analysis by Late Stage Development, H2 2016 112 Comparative Analysis by Clinical Stage Development, H2 2016 113 Comparative Analysis by Early Stage Development, H2 2016 114 Comparative Analysis by Unknown Stage Development, H2 2016 115 Products under Development by Companies, H2 2016 116 Products under Development by Companies, H2 2016 (Contd..1) 117 Products under Development by Companies, H2 2016 (Contd..2) 118 Products under Development by Companies, H2 2016 (Contd..3) 119 Products under Development by Companies, H2 2016 (Contd..4) 120 Products under Development by Companies, H2 2016 (Contd..5) 121 Products under Development by Companies, H2 2016 (Contd..6) 122 Products under Development by Companies, H2 2016 (Contd..7) 123 Products under Development by Companies, H2 2016 (Contd..8) 124 Products under Development by Companies, H2 2016 (Contd..9) 125 Products under Development by Companies, H2 2016 (Contd..10) 126 Products under Development by Companies, H2 2016 (Contd..11) 127 Products under Development by Companies, H2 2016 (Contd..12) 128 Products under Development by Companies, H2 2016 (Contd..13) 129 Products under Development by Companies, H2 2016 (Contd..14) 130 Products under Development by Companies, H2 2016 (Contd..15) 131 Products under Development by Companies, H2 2016 (Contd..16) 132 Products under Development by Companies, H2 2016 (Contd..17) 133 Products under Development by Companies, H2 2016 (Contd..18) 134 Products under Development by Companies, H2 2016 (Contd..19) 135 Products under Development by Companies, H2 2016 (Contd..20) 136 Products under Development by Companies, H2 2016 (Contd..21) 137 Products under Development by Companies, H2 2016 (Contd..22) 138 Products under Development by Companies, H2 2016 (Contd..23) 139 Products under Development by Companies, H2 2016 (Contd..24) 140 Products under Development by Companies, H2 2016 (Contd..25) 141 Products under Development by Companies, H2 2016 (Contd..26) 142 Products under Development by Companies, H2 2016 (Contd..27) 143 Products under Development by Companies, H2 2016 (Contd..28) 144 Products under Development by Companies, H2 2016 (Contd..29) 145 Products under Development by Companies, H2 2016 (Contd..30) 146 Products under Development by Companies, H2 2016 (Contd..31) 147 Products under Development by Companies, H2 2016 (Contd..32) 148 Products under Development by Companies, H2 2016 (Contd..33) 149 Products under Development by Companies, H2 2016 (Contd..34) 150 Products under Investigation by Universities/Institutes, H2 2016 151 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 152 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 153 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 154 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 155 Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 156 Pancreatic Cancer - Pipeline by 4SC AG, H2 2016 157 Pancreatic Cancer - Pipeline by AB Science SA, H2 2016 158 Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016 159 Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016 160 Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 161 Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 162 Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016 163 Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 164 Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016 165 Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016 166 Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016 167 Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016 168 Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016 169 Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 170 Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016 171 Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016 172 Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016 173 Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016 174 Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016 175 Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016 176 Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016 177 Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 178 Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016 179 Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 180 Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 181 Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016 182 Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016 183 Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016 184 Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016 185 Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016 186 Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016 187 Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016 188 Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 189 Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016 190 Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016 191 Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192 Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016 193 Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 194 Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 195 Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 196 Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 197 Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 198 Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 199 Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200 Pancreatic Cancer - Pipeline by Bayer AG, H2 2016 201 Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016 202 Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 203 Pancreatic Cancer - Pipeline by Berg LLC, H2 2016 204 Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016 205 Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 206 Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 207 Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 208 Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 209 Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016 210 Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016 211 Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016 212 Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 213 Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016 214 Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016 215 Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016 216 Pancreatic Cancer - Pipeline by Biotest AG, H2 2016 217 Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016 218 Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016 219 Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220 Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221 Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222 Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016 223 Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 224 Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016 225 Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 226 Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016 227 Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016 228 Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016 229 Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 230 Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016 231 Pancreatic Cancer - Pipeline by Celyad SA, H2 2016 232 Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016 233 Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016 234 Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016 235 Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 236 Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 237 Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016 238 Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 239 Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016 240 Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016 241 Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242 Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 243 Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016 244 Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016 245 Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 246 Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 247
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
